CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Sunitinibdrug
Likely dose
Sunitinib 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00599313
NCT00599313Phase 2Completed
CompareCT.gov

Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy

US Oncology Research·interventional·Posted Jan 23, 2008·Updated Oct 25, 2018

In Brief

A Phase 2 clinical trial evaluating Sunitinib for Metastatic Prostate Cancer. Completed, enrolled 36 participants across 45 sites.

Detailed Summary

The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Prostate Cancer
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 23, 2008
Enrollment StartMar 1, 2007
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.4 years ago

Interventions

Sunitinibdrug

50 mg/day orally each of Days 1-28 of each 6 week cycle